IL17A and Alzheimer disease: Specifically, we found that after 2 months of twice-daily TEMT (1-h treatments), mild/moderate AD subjects exhibited a rebalancing of 11 of 12 cytokines in their plasma: GCSF, GMCSF, VEGF, PDGF, IL-8, IL-10, IL-15, IL-17α, IL-18, TGF-α, and IFN-γ [53].